Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

CAPS Rating: 2 out of 5

The Company is engaged in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, and asthma/allergies, and for use as vaccine adjuvants.

Recs

3
Player Avatar zzlangerhans (99.78) Submitted: 3/18/2009 12:26:49 PM : Underperform Start Price: $7.38 IDRA Score: +14.94

In October the lead compound IMO2055 failed a phase II trial for renal cell carcinoma. What kept the stock from tanking more than 25% on the bad news, considering that the whole pipeline consists of related TLR9 agonists and antagonists? Probably the significant number of collaborations with big pharma which has kept the quarterly burn close to zero. A company which doesn't lose money will never go out of business, right? But naturally, when trials fail the next thing to go will be the partnerships. When collaboration revenues vanish then the burn will appear. And then the stock will drop.

Member Avatar zzlangerhans (99.78) Submitted: 3/26/2009 11:46:07 AM
Recs: 0

Idera has been bouncing like a rubber ball. I'll rate it again once it exits the mid-zone of recent range.

Featured Broker Partners


Advertisement